Symbols / CTSO Stock $0.50 -8.16% Cytosorbents Corporation

Healthcare • Medical Devices • United States • NCM
CTSO (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Medical Devices
CEO Dr. Phillip P. Chan M.D., Ph.D.
Exch · Country NCM · United States
Market Cap 31.25M
Enterprise Value 55.71M
Income -11.85M
Sales 37.20M
FCF (ttm) -4.68M
Book/sh 0.04
Cash/sh 0.08
Employees 129
Insider 10d —
IPO Aug 08, 2006
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E inf
PEG —
P/S 0.84
P/B 14.22
P/C —
EV/EBITDA -4.67
EV/Sales 1.50
Quick Ratio 0.73
Current Ratio 1.09
Debt/Eq 1,334.37
LT Debt/Eq —
EPS (ttm) -0.19
EPS next Y 0.00
EPS Growth —
Revenue Growth 1.60%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-08-06
Earnings (prior) 2026-05-13
ROA -18.33%
ROE -141.58%
ROIC —
Gross Margin 71.00%
Oper. Margin -34.34%
Profit Margin -31.85%
Shs Outstand 62.79M
Shs Float 55.09M
Insider Own 14.85%
Instit Own 26.41%
Short Float 3.35%
Short Ratio 27.78
Short Interest 2.04M
52W High 1.39
vs 52W High -64.20%
52W Low 0.49
vs 52W Low 1.22%
Beta —
Impl. Vol. 1.17%
Rel Volume 2.23
Avg Volume 85.23K
Volume 190.00K
Target (mean) $5.25
Tgt Median $5.00
Tgt Low $0.75
Tgt High $10.00
# Analysts 3
Recom Buy
Prev Close $0.54
Price $0.50
Change -8.16%
About

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform in the United States, Germany, and internationally. Its flagship product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses, bilirubin in liver failure, myoglobin in trauma and critical illnesses, and inflammatory mediators and blood thinners in cardiac surgery applications, as well as to remove antithrombotic drugs and inflammatory mediators in cardiothoracic surgery applications. The company also develops DrugSorb-ATR antithrombotic removal system, an investigational device to reduce the severity of perioperative bleeding in high-risk surgery due to blood thinning drugs; ECOS-300CY to reduce cytokines and other inflammatory mediators when used in an ex vivo organ perfusion system; VetResQ, a broad-spectrum blood purification adsorber for the treatment of septic shock, toxic shock syndrome, toxin-mediated diseases, pancreatitis, trauma, liver failure, heat stroke, and lung injury in animals; and PuriFi, an advanced hemoperfusion pump for blood purification therapies. In addition, it develops HemoDefend-BGA, a blood purification technology platform to reduce anti-A and anti-B antibodies in plasma and whole blood. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$5.25
Mean price target
2. Current target
$0.50
Latest analyst target
3. DCF / Fair value
$-1.34
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.50
Low
$0.75
High
$10.00
Mean
$5.25

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-26 main D. Boral Capital Buy → Buy $10
2026-01-12 main D. Boral Capital Buy → Buy $10
2025-12-16 main D. Boral Capital Buy → Buy $10
2025-11-14 main D. Boral Capital Buy → Buy $10
2025-11-14 main HC Wainwright & Co. Neutral → Neutral $1
2025-09-16 main D. Boral Capital Buy → Buy $10
2025-08-20 main D. Boral Capital Buy → Buy $10
2025-08-08 main D. Boral Capital Buy → Buy $10
2025-07-21 main D. Boral Capital Buy → Buy $10
2025-06-25 main D. Boral Capital Buy → Buy $10
2025-05-15 main D. Boral Capital Buy → Buy $10
2025-05-15 reit HC Wainwright & Co. Neutral → Neutral $1
2025-05-02 main D. Boral Capital Buy → Buy $10
2025-04-03 reit HC Wainwright & Co. Neutral → Neutral $1
2025-04-01 main D. Boral Capital Buy → Buy $10
2025-02-25 main D. Boral Capital Buy → Buy $10
2025-01-13 main D. Boral Capital Buy → Buy $10
2025-01-03 main D. Boral Capital Buy → Buy $10
2024-11-12 main D. Boral Capital Buy → Buy $10
2024-11-11 reit HC Wainwright & Co. Neutral → Neutral $1
News
RSS: Latest CTSO news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2025-11-18 CHAN PHILLIP P Chief Executive Officer — 100,000 $0.64 $64,000
2025-08-08 CAPPONI VINCENT J President — 89,100 $0.00 $0
2025-08-08 MARIANI PETER J Chief Financial Officer — 71,500 $0.00 $0
2025-08-08 CHAN PHILLIP P Chief Executive Officer — 105,600 $0.00 $0
2025-08-08 DELIARGYRIS EFTHYMIOS Officer — 70,000 $0.00 $0
2025-02-24 CAPPONI VINCENT J President — 12,000 $1.13 $13,560
2025-02-24 MARIANI PETER J Chief Financial Officer — 32,625 $1.13 $36,866
2025-02-24 CHAN PHILLIP P Chief Executive Officer — 34,168 $1.13 $38,610
2025-02-24 SOBEL ALAN D Director — 21,950 $1.13 $24,804
2025-02-24 BATOR MICHAEL G. Director — 10,000 $1.13 $11,300
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
37.06
+4.12%
35.59
+14.51%
31.08
+5.88%
29.36
Operating Revenue
37.06
+4.12%
35.59
+14.51%
31.08
+5.88%
29.36
Cost Of Revenue
10.57
-1.27%
10.71
+17.26%
9.13
-34.57%
13.96
Reconciled Cost Of Revenue
10.57
-1.27%
10.71
+17.26%
9.13
-34.57%
13.96
Gross Profit
26.49
+6.45%
24.89
+13.36%
21.95
+42.52%
15.40
Operating Expense
40.73
-1.47%
41.34
-23.31%
53.90
+14.87%
46.93
Research And Development
5.08
-33.15%
7.61
-51.22%
15.59
+3.15%
15.12
Selling General And Administration
35.65
+5.67%
33.73
-11.94%
38.31
+3.15%
37.14
General And Administrative Expense
—
—
37.87
+1.98%
37.14
Other Gand A
—
—
37.87
+1.98%
37.14
Other Operating Expenses
—
—
-5.26
+1.21%
-5.33
Total Expenses
51.30
-1.43%
52.05
-17.43%
63.03
+3.53%
60.88
Operating Income
-14.24
+13.45%
-16.45
+48.50%
-31.95
-1.35%
-31.52
Total Operating Income As Reported
-14.75
+10.35%
-16.45
+48.50%
-31.95
-1.35%
-31.52
EBITDA
-4.36
+77.39%
-19.27
+30.89%
-27.88
+8.26%
-30.39
Normalized EBITDA
-13.17
+12.47%
-15.04
+49.57%
-29.83
-6.75%
-27.94
Reconciled Depreciation
1.63
-6.48%
1.74
-13.81%
2.02
+78.81%
1.13
EBIT
-5.99
+71.51%
-21.01
+29.74%
-29.90
+5.14%
-31.52
Total Unusual Items
8.81
+308.54%
-4.22
-316.75%
1.95
+179.61%
-2.45
Total Unusual Items Excluding Goodwill
8.81
+308.54%
-4.22
-316.75%
1.95
+179.61%
-2.45
Special Income Charges
-0.51
0.00
—
—
Restructuring And Mergern Acquisition
0.51
0.00
—
—
Net Income
-8.20
+60.43%
-20.72
+29.16%
-29.25
+10.87%
-32.81
Pretax Income
-8.60
+61.63%
-22.41
+25.45%
-30.06
+11.34%
-33.91
Net Non Operating Interest Income Expense
-2.61
-86.70%
-1.40
-786.05%
-0.16
-219.08%
0.13
Interest Expense Non Operating
2.61
+86.70%
1.40
+786.05%
0.16
—
Net Interest Income
-2.61
-86.70%
-1.40
-786.05%
-0.16
-219.08%
0.13
Interest Expense
2.61
+86.70%
1.40
+786.05%
0.16
—
Interest Income Non Operating
—
—
—
—
Interest Income
—
—
—
—
Other Income Expense
8.25
+281.00%
-4.56
-322.82%
2.05
+181.32%
-2.52
Other Non Operating Income Expenses
-0.56
-67.37%
-0.33
-445.20%
0.10
+243.76%
-0.07
Gain On Sale Of Security
9.32
+320.62%
-4.22
-316.75%
1.95
+179.61%
-2.45
Tax Provision
-0.40
+76.29%
-1.69
-107.81%
-0.81
+25.52%
-1.09
Tax Rate For Calcs
0.00
-37.71%
0.00
+179.47%
0.00
-15.63%
0.00
Tax Effect Of Unusual Items
0.41
+229.90%
-0.32
-705.75%
0.05
+167.17%
-0.08
Net Income Including Noncontrolling Interests
-8.20
+60.43%
-20.72
+29.16%
-29.25
+10.87%
-32.81
Net Income From Continuing Operation Net Minority Interest
-8.20
+60.43%
-20.72
+29.16%
-29.25
+10.87%
-32.81
Net Income From Continuing And Discontinued Operation
-8.20
+60.43%
-20.72
+29.16%
-29.25
+10.87%
-32.81
Net Income Continuous Operations
-8.20
+60.43%
-20.72
+29.16%
-29.25
+10.87%
-32.81
Normalized Income
-16.59
+1.30%
-16.81
+46.01%
-31.14
-2.30%
-30.44
Net Income Common Stockholders
-8.20
+60.43%
-20.72
+29.16%
-29.25
+10.87%
-32.81
Diluted EPS
-0.13
+65.79%
-0.38
+41.54%
-0.65
+12.90%
-0.75
Basic EPS
-0.13
+65.79%
-0.38
+41.54%
-0.65
+12.90%
-0.75
Basic Average Shares
62.23
+14.32%
54.43
+21.90%
44.66
+1.98%
43.79
Diluted Average Shares
62.23
+14.32%
54.43
+21.90%
44.66
+1.98%
43.79
Diluted NI Availto Com Stockholders
-8.20
+60.43%
-20.72
+29.16%
-29.25
+10.87%
-32.81
Total Other Finance Cost
—
—
0.16
+219.08%
-0.13
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
44.18
-6.73%
47.37
-10.55%
52.96
-16.25%
63.23
Current Assets
20.63
-4.49%
21.60
-14.94%
25.40
-24.77%
33.76
Cash Cash Equivalents And Short Term Investments
6.25
+90.52%
3.28
-76.79%
14.13
-36.19%
22.14
Cash And Cash Equivalents
6.25
+90.52%
3.28
-76.79%
14.13
-36.19%
22.14
Receivables
7.55
+3.14%
7.32
+20.85%
6.06
+6.92%
5.66
Accounts Receivable
7.55
+3.14%
7.32
+20.85%
6.06
+6.92%
5.66
Gross Accounts Receivable
7.71
+3.16%
7.48
+22.45%
6.11
+6.37%
5.74
Allowance For Doubtful Accounts Receivable
-0.16
-3.80%
-0.16
-218.14%
-0.05
+34.69%
-0.08
Inventory
5.28
+93.23%
2.73
-19.04%
3.38
-2.48%
3.46
Raw Materials
0.75
+31.75%
0.57
-16.89%
0.69
+11.81%
0.61
Work In Process
1.01
+101.59%
0.50
-40.04%
0.84
-34.48%
1.28
Finished Goods
3.53
+112.53%
1.66
-10.33%
1.85
+18.07%
1.57
Prepaid Assets
—
—
—
—
Restricted Cash
0.00
-100.00%
5.00
0.00
—
Other Current Assets
1.55
-52.49%
3.27
+78.31%
1.83
-26.28%
2.49
Total Non Current Assets
23.55
-8.62%
25.77
-6.49%
27.56
-6.49%
29.47
Net PPE
18.75
-8.61%
20.51
-7.25%
22.12
-5.28%
23.35
Gross PPE
23.89
-3.42%
24.74
-1.64%
25.15
-0.37%
25.24
Accumulated Depreciation
-5.15
-21.77%
-4.23
-39.19%
-3.04
-60.07%
-1.90
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
6.66
-4.09%
6.95
+1.13%
6.87
+6.67%
6.44
Other Properties
10.92
-5.10%
11.51
-4.54%
12.06
-4.32%
12.60
Leases
6.31
+0.40%
6.28
+0.93%
6.22
+0.38%
6.20
Goodwill And Other Intangible Assets
3.23
-13.30%
3.72
-4.75%
3.91
-11.02%
4.39
Other Intangible Assets
3.23
-13.30%
3.72
-4.75%
3.91
-11.02%
4.39
Non Current Prepaid Assets
—
0.02
-56.50%
0.05
+10.95%
0.05
Other Non Current Assets
1.57
+2.67%
1.53
+3.37%
1.48
-12.06%
1.69
Total Liabilities Net Minority Interest
38.28
+5.55%
36.27
+23.04%
29.48
+5.81%
27.86
Current Liabilities
9.71
-1.18%
9.82
-30.00%
14.04
+44.48%
9.71
Payables And Accrued Expenses
7.93
-1.53%
8.05
-8.37%
8.79
+8.66%
8.09
Payables
2.87
-14.10%
3.34
-12.16%
3.80
+51.73%
2.51
Accounts Payable
2.87
-14.10%
3.34
-12.16%
3.80
+51.73%
2.51
Other Payable
—
—
—
0.02
Current Accrued Expenses
5.06
+7.38%
4.71
-5.48%
4.99
-10.67%
5.58
Current Debt And Capital Lease Obligation
0.54
+19.43%
0.45
-84.24%
2.87
+2537.84%
0.11
Current Debt
—
—
2.50
—
Other Current Borrowings
—
—
2.50
—
Current Capital Lease Obligation
0.54
+19.43%
0.45
+21.24%
0.37
+242.98%
0.11
Current Deferred Liabilities
0.33
-51.39%
0.68
-50.54%
1.38
-8.96%
1.52
Current Deferred Revenue
0.33
-51.39%
0.68
-50.54%
1.38
-8.96%
1.52
Other Current Liabilities
0.91
+42.52%
0.64
-35.96%
0.99
—
Total Non Current Liabilities Net Minority Interest
28.57
+8.06%
26.44
+71.25%
15.44
-14.90%
18.14
Long Term Debt And Capital Lease Obligation
28.57
+8.06%
26.44
+71.25%
15.44
-14.90%
18.14
Long Term Debt
16.67
+19.08%
14.00
+450.40%
2.54
-49.14%
5.00
Long Term Capital Lease Obligation
11.90
-4.35%
12.44
-3.51%
12.90
-1.87%
13.14
Stockholders Equity
5.90
-46.85%
11.11
-52.70%
23.48
-33.62%
35.37
Common Stock Equity
5.90
-46.85%
11.11
-52.70%
23.48
-33.62%
35.37
Capital Stock
0.06
+14.55%
0.06
+1.40%
0.05
+24.30%
0.04
Common Stock
0.06
+14.55%
0.06
+1.40%
0.05
+24.30%
0.04
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
62.80
+13.98%
55.10
+1.09%
54.51
+24.30%
43.85
Ordinary Shares Number
62.80
+13.98%
55.10
+1.09%
54.51
+24.30%
43.85
Additional Paid In Capital
321.02
+3.29%
310.81
+1.51%
306.19
+6.69%
287.00
Retained Earnings
-312.21
-2.70%
-304.01
-7.31%
-283.29
-11.53%
-254.00
Gains Losses Not Affecting Retained Earnings
-2.98
-170.01%
4.25
+703.29%
0.53
-77.27%
2.33
Other Equity Adjustments
-2.98
-170.01%
4.25
+703.29%
0.53
-77.27%
2.33
Total Equity Gross Minority Interest
5.90
-46.85%
11.11
-52.70%
23.48
-33.62%
35.37
Total Capitalization
22.57
-10.09%
25.10
-3.54%
26.02
-35.54%
40.37
Working Capital
10.93
-7.25%
11.78
+3.66%
11.36
-52.74%
24.05
Invested Capital
22.57
-10.09%
25.10
-11.99%
28.52
-29.35%
40.37
Total Debt
29.11
+8.25%
26.89
+46.85%
18.31
+0.34%
18.25
Net Debt
10.42
-2.78%
10.72
—
—
Capital Lease Obligations
12.44
-3.51%
12.90
-2.81%
13.27
+0.15%
13.25
Net Tangible Assets
2.68
-63.76%
7.39
-62.27%
19.57
-36.82%
30.98
Tangible Book Value
2.68
-63.76%
7.39
-62.27%
19.57
-36.82%
30.98
Interest Payable
—
—
0.03
+519.94%
0.01
Inventories Adjustments Allowances
-0.01
0.00
—
—
Other Inventories
—
-0.30
—
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-12.38
+14.22%
-14.43
+33.37%
-21.66
+23.30%
-28.23
Cash Flow From Continuing Operating Activities
-12.38
+14.22%
-14.43
+33.37%
-21.66
+23.30%
-28.23
Net Income From Continuing Operations
-8.20
+60.43%
-20.72
+29.16%
-29.25
+10.87%
-32.81
Depreciation Amortization Depletion
1.63
-6.48%
1.74
-13.81%
2.02
+78.81%
1.13
Depreciation
1.37
-9.28%
1.51
-25.42%
2.02
+78.81%
1.13
Amortization Cash Flow
0.26
+11.49%
0.23
—
—
Depreciation And Amortization
1.63
-6.48%
1.74
-13.81%
2.02
+78.81%
1.13
Amortization Of Intangibles
0.26
+11.49%
0.23
—
—
Other Non Cash Items
0.82
+66.67%
0.49
+1048.00%
0.04
—
Stock Based Compensation
2.77
-26.46%
3.76
-9.51%
4.16
+9.35%
3.80
Asset Impairment Charge
0.96
+112.92%
0.45
-33.00%
0.67
+6.83%
0.63
Operating Gains Losses
-9.32
-320.62%
4.22
+316.75%
-1.95
-175.53%
2.58
Net Foreign Currency Exchange Gain Loss
-9.32
-320.62%
4.22
+316.75%
-1.95
-179.61%
2.45
Gain Loss On Sale Of PPE
—
—
0.00
-100.00%
0.13
Change In Working Capital
-1.03
+76.48%
-4.38
-265.30%
2.65
+174.38%
-3.56
Change In Receivables
0.42
+124.59%
-1.72
-600.28%
-0.25
+80.94%
-1.29
Changes In Account Receivables
—
—
—
-1.29
Change In Inventory
-2.54
-608.00%
0.50
+172.82%
0.18
-80.61%
0.95
Change In Prepaid Assets
1.79
+232.47%
-1.35
-222.45%
1.10
+5076.64%
-0.02
Change In Payables And Accrued Expense
-0.71
+60.95%
-1.81
-212.48%
1.61
+149.47%
-3.25
Change In Other Current Assets
0.00
+100.00%
0.00
+2140.82%
-0.00
-100.09%
0.05
Investing Cash Flow
-0.41
+37.97%
-0.67
+28.54%
-0.94
+85.50%
-6.46
Cash Flow From Continuing Investing Activities
-0.41
+37.97%
-0.67
+28.54%
-0.94
+85.50%
-6.46
Net PPE Purchase And Sale
-0.09
+69.01%
-0.28
+47.22%
-0.54
+91.16%
-6.09
Purchase Of PPE
-0.16
+42.25%
-0.28
+47.22%
-0.54
+91.16%
-6.09
Sale Of PPE
0.08
0.00
—
—
Capital Expenditure
-0.49
+26.61%
-0.67
+28.54%
-0.94
+85.50%
-6.46
Net Intangibles Purchase And Sale
-0.33
+15.06%
-0.39
+3.30%
-0.40
-8.12%
-0.37
Purchase Of Intangibles
-0.33
+15.06%
-0.39
+3.30%
-0.40
-8.12%
-0.37
Financing Cash Flow
9.31
-0.24%
9.33
-35.53%
14.47
+191.84%
4.96
Cash Flow From Continuing Financing Activities
9.31
-0.24%
9.33
-35.53%
14.47
+191.84%
4.96
Net Issuance Payments Of Debt
2.48
-75.22%
10.00
0.00
-100.00%
5.00
Issuance Of Debt
2.48
-83.48%
15.00
0.00
-100.00%
5.00
Repayment Of Debt
0.00
+100.00%
-5.00
0.00
0.00
Long Term Debt Issuance
2.48
-83.48%
15.00
0.00
-100.00%
5.00
Long Term Debt Payments
0.00
+100.00%
-5.00
0.00
0.00
Net Long Term Debt Issuance
2.48
-75.22%
10.00
0.00
-100.00%
5.00
Net Common Stock Issuance
5.39
+2912.29%
0.18
-98.74%
14.26
+35423.68%
-0.04
Common Stock Payments
—
—
—
-0.04
Repurchase Of Capital Stock
—
—
—
-0.04
Proceeds From Stock Option Exercised
1.44
0.00
-100.00%
0.22
0.00
Net Other Financing Charges
—
-0.85
—
—
Changes In Cash
-3.48
+39.59%
-5.77
+28.97%
-8.12
+72.70%
-29.73
Effect Of Exchange Rate Changes
1.49
+1852.94%
-0.09
+14.80%
-0.10
+62.05%
-0.26
Beginning Cash Position
9.76
-37.47%
15.62
-34.48%
23.83
-55.72%
53.83
End Cash Position
7.77
-20.41%
9.76
-37.47%
15.62
-34.48%
23.83
Free Cash Flow
-12.87
+14.76%
-15.10
+33.17%
-22.59
+34.88%
-34.69
Interest Paid Supplemental Data
2.08
+61.40%
1.29
+242.48%
0.38
0.00
Common Stock Issuance
5.39
+2912.29%
0.18
-98.74%
14.26
—
Issuance Of Capital Stock
5.39
+2912.29%
0.18
-98.74%
14.26
—
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category